UBS lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $546 from $553 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating
- FDA awards second batch of National Priority Vouchers
- Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights
- Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration
- Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital